VKTX (Viking Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics 3-Year Dividend Growth Rate?

Viking Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The historical rank and industry rank for Viking Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

VKTX's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Viking Therapeutics's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Viking Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Viking Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Viking Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's 3-Year Dividend Growth Rate falls into.

Viking Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Viking Therapeutics (NAS:VKTX) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Viking Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-0.221
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics 3-Year Dividend Growth Rate Related Terms>

Viking Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (NAS:VKTX) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

0VQA:UK 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Executives

Lawson Macartney	director	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Greg Zante	officer: Chief Financial Officer	C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804
Sarah Kathryn Rouan	director	4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
J Matthew Singleton	director	286 STANWICH ROAD, GREENWICH CT 06830
Brian Lian	director, officer: President & CEO	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Marianna Mancini	officer: Chief Operating Officer	C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Matthew W Foehr	director	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Ligand Pharmaceuticals Inc	10 percent owner	3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Hiroko Masamune	officer: Chief Development Officer	C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Michael Morneau	officer: Chief Financial Officer	C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Stephen W Webster	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Rochelle Hanley	officer: Chief Medical Officer	C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037
Michael Dinerman	officer: Chief Operating Officer	C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037